SCHEMBL15874337

SCHEMBL15874337

C=C(C)OC(=O)Nc1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
PKM P14618 1/20 0.53
LMNA P02545 2/20 0.51
HIF1A Q16665 1/20 0.51
KDM4E B2RXH2 4/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 2/20 0.51
NAMPT P43490 3/20 0.51
KMT2A Q03164 2/20 0.51
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352289 0.82 KDM4E (0.62) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL1070561 0.82 KDM4E (0.62) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL12606901 0.80 NAPRT (0.55) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL12828408 0.79 RAB9A (0.67) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL49506 0.78 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL12447388 0.78 LMNA (0.57) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL29602550 0.78 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A
Hydrochloric Acid SCHEMBL5095381 0.76 RAB9A (0.62) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL966665 0.76 NPC1 (0.59) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL349933 0.76 NAMPT (0.80) RAB9ANPC1PKMLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970122-B1 SHIP1 MODULATORS AQUINOX PHARMACEUTICALS CANADA INC (CA) 2019-05-08 EP disclosed
EP-2970122-B1 SHIP1 MODULATORS AQUINOX PHARMACEUTICALS CANADA INC (CA) 2019-05-08 EP disclosed
US-10272081-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) 2019-04-30 US disclosed
US-10272081-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) 2019-04-30 US disclosed
US-10174046-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) 2019-01-08 US disclosed
US-20180360828-A9 SHIP1 MODULATORS AND METHODS RELATED THERETO NEOLEUKIN THERAPEUTICS, INC. 2018-12-20 US disclosed
CN-108892637-A SHIP1 regulator and relative method 阿奎诺克斯药物(加拿大)公司 2018-11-27 CN disclosed
CN-108752236-A SHIP1 conditioning agents and relative method 阿奎诺克斯药物(加拿大)公司 2018-11-06 CN disclosed
CN-105164108-B SHIP1 modulators and methods related thereto 阿奎诺克斯药物(加拿大)公司 2018-07-17 CN disclosed
US-20180161324-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS CANADA INC (CA) 2018-06-14 US disclosed
US-20160031899-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS CANADA INC (CA) 2016-02-04 US disclosed
US-20160031899-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS CANADA INC (CA) 2016-02-04 US disclosed
EP-2970122-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO Aquinox Pharmaceuticals (Canada) Inc. (CA) 2016-01-20 EP disclosed
US-20150336935-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS CANADA INC (CA) 2015-11-26 US disclosed
US-20150336935-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS CANADA INC (CA) 2015-11-26 US disclosed
EP-2943470-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO Aquinox Pharmaceuticals (Canada) Inc. (CA) 2015-11-18 EP disclosed
WO-2014158654-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2014-10-02 WO disclosed
WO-2014158654-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2014-10-02 WO disclosed
WO-2014110036-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2014-07-17 WO disclosed
WO-2014110036-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2014-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10272081-B2 SHIP1 modulators and methods related thereto PPP1R1B, PPM1A, PPM1D RAB9A 724/4885NPC1 776/4885PKM 4600/4885
US-20150336935-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1A, PPM1D, PPP1R1B RAB9A 637/4885NPC1 702/4885PKM 4575/4885
US-10174046-B2 SHIP1 modulators and methods related thereto PPM1D, PPP1R7, PPM1A RAB9A 1329/4885NPC1 1709/4885PKM 4337/4885
US-20180360828-A9 SHIP1 MODULATORS AND METHODS RELATED THERETO PPP1R1B, PPM1A, PPM1D RAB9A 724/4885NPC1 776/4885PKM 4600/4885
US-20180161324-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPP1R1B, PPM1A, PPM1D RAB9A 724/4885NPC1 776/4885PKM 4600/4885
US-20160031899-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PPM1A, PPP1R7 RAB9A 1215/4885NPC1 1707/4885PKM 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.